Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis

William Weiss, Mark E. Pulse, Phung Nguyen, Kelly Peterson, Jessica Silva, Jerry Simecka, David Valtierra, Mojgan Sabet, David C. Griffith

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae. We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPCproducing, carbapenem-resistant Enterobacteriaceae.

Original languageEnglish
Article numbere01439
JournalAntimicrobial agents and chemotherapy
Volume62
Issue number1
DOIs
StatePublished - 1 Jan 2018

Fingerprint

meropenem
Carbapenems
Pyelonephritis
Enterobacteriaceae
Klebsiella pneumoniae
Urinary Tract Infections

Keywords

  • KPC
  • Klebsiella pneumoniae carbapenemase
  • Meropenem
  • Pyelonephritis
  • Vaborbactam

Cite this

Weiss, William ; Pulse, Mark E. ; Nguyen, Phung ; Peterson, Kelly ; Silva, Jessica ; Simecka, Jerry ; Valtierra, David ; Sabet, Mojgan ; Griffith, David C. / Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis. In: Antimicrobial agents and chemotherapy. 2018 ; Vol. 62, No. 1.
@article{612c6c4feb804032ad45fd0c39ea096b,
title = "Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis",
abstract = "The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae. We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPCproducing, carbapenem-resistant Enterobacteriaceae.",
keywords = "KPC, Klebsiella pneumoniae carbapenemase, Meropenem, Pyelonephritis, Vaborbactam",
author = "William Weiss and Pulse, {Mark E.} and Phung Nguyen and Kelly Peterson and Jessica Silva and Jerry Simecka and David Valtierra and Mojgan Sabet and Griffith, {David C.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1128/AAC.01439-17",
language = "English",
volume = "62",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",

}

Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis. / Weiss, William; Pulse, Mark E.; Nguyen, Phung; Peterson, Kelly; Silva, Jessica; Simecka, Jerry; Valtierra, David; Sabet, Mojgan; Griffith, David C.

In: Antimicrobial agents and chemotherapy, Vol. 62, No. 1, e01439, 01.01.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis

AU - Weiss, William

AU - Pulse, Mark E.

AU - Nguyen, Phung

AU - Peterson, Kelly

AU - Silva, Jessica

AU - Simecka, Jerry

AU - Valtierra, David

AU - Sabet, Mojgan

AU - Griffith, David C.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae. We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPCproducing, carbapenem-resistant Enterobacteriaceae.

AB - The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae. We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPCproducing, carbapenem-resistant Enterobacteriaceae.

KW - KPC

KW - Klebsiella pneumoniae carbapenemase

KW - Meropenem

KW - Pyelonephritis

KW - Vaborbactam

UR - http://www.scopus.com/inward/record.url?scp=85039804469&partnerID=8YFLogxK

U2 - 10.1128/AAC.01439-17

DO - 10.1128/AAC.01439-17

M3 - Article

C2 - 29038270

AN - SCOPUS:85039804469

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 1

M1 - e01439

ER -